Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 365
- Registration Number
- NCT00250653
- Locations
- 🇺🇸
Administrative Office, Bridgewater, New Jersey, United States
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 452
- Registration Number
- NCT00250614
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
- Conditions
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7554
- Registration Number
- NCT00249873
- Locations
- 🇧🇪
Sanofi-aventis Administrative Office, Diegem, Belgium
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇹Sanofi-Aventis, Wien, Austria
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
- Conditions
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9016
- Registration Number
- NCT00249795
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
SOLIACS: Solian Solution in the Acute Setting
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT00245674
- Locations
- 🇧🇪
Sanofi-aventis, Diegem, Belgium
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-10-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6706
- Registration Number
- NCT00243178
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 803
- Registration Number
- NCT00239967
- Locations
- 🇨🇳
Sanofi-aventis Administrative Office, Taipei, Taiwan
A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2008-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 394
- Registration Number
- NCT00239174
- Locations
- 🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia
🇪🇸Sanofi-Aventis Administrative Office, Barcelona, Spain
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 110
- Registration Number
- NCT00237445
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 673
- Registration Number
- NCT00233441
- Locations
- 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia